FS118
Metastatic, PD-1 resistant cancers (e.g., Head & Neck, DLBCL)
Key Facts
About F-star Therapeutics
F-star Therapeutics is a UK-based biotech focused on creating next-generation bispecific antibodies for immuno-oncology. Its core achievement is the development of the proprietary Fcab and mAb2 platforms, which generate tetravalent, IgG-like bispecific antibodies designed for enhanced stability, manufacturability, and biological activity. The company's strategy involves advancing its internal pipeline of clinical and preclinical assets while securing strategic partnerships to validate and expand the utility of its modular technology. Following its NASDAQ IPO in 2020, F-star has progressed key assets into clinical trials, positioning itself in the competitive bispecific antibody landscape.
View full company profile